Related Experiment Video
Updated: Jan 22, 2026

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Rachael M Zemek1,2, Emma De Jong3, Wee Loong Chin2,4,5
1School of Biomedical Sciences, University of Western Australia, M503, Crawley, WA 6009, Australia.
Abstract:
Cancer immunotherapy using antibodies that target immune checkpoints has delivered outstanding results. However, responses only occur in a subset of patients, and it is not fully understood what biological processes determine an effective outcome. This lack of understanding hinders the development of rational combination treatments. We set out to define the pretreatment microenvironment associated with an effective outcome by using the fact that inbred mouse strains bearing monoclonal cancer cell line-derived tumors respond in a dichotomous manner to immune checkpoint blockade (ICB). We compared the cellular composition and gene expression profiles of responsive and nonresponsive tumors from mice before ICB and validated the findings in cohorts of patients with cancer treated with ICB antibodies. We found that responsive tumors were characterized by an inflammatory gene expression signature consistent with up-regulation of signal transducer and activator of transcription 1 (STAT1) and Toll-like receptor 3 (TLR3) signaling and down-regulation of interleukin-10 (IL-10) signaling. In addition, responsive tumors had more infiltrating-activated natural killer (NK) cells, which were necessary for response. Pretreatment of mice with large established tumors using the STAT1-activating cytokine interferon-γ (IFNγ), the TLR3 ligand poly(I:C), and an anti-IL-10 antibody sensitized tumors to ICB by attracting IFNγ-producing NK cells into the tumor, resulting in increased cure rates. Our results identify a pretreatment tumor microenvironment that predicts response to ICB, which can be therapeutically attained. These data suggest a biomarker-driven approach to patient management to establish whether a patient would benefit from treatment with sensitizing therapeutics before ICB.
Insights
Identifying the tumor microenvironment is key for effective cancer immunotherapy. Responsive tumors show specific inflammatory signals and natural killer (NK) cells, which can be therapeutically enhanced to improve treatment outcomes.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Cancer immunotherapy, particularly immune checkpoint blockade (ICB), shows promise but benefits only a subset of patients.
- Understanding the biological factors determining ICB response is crucial for developing effective combination treatments.
- Inbred mouse models with dichotomous responses to ICB offer a platform to study pretreatment tumor microenvironments.
Purpose of the Study:
- To define the pretreatment tumor microenvironment associated with effective responses to cancer immunotherapy.
- To identify biomarkers predictive of response to immune checkpoint blockade (ICB).
- To explore therapeutic strategies to sensitize nonresponsive tumors to ICB.
Main Methods:
- Comparative analysis of cellular composition and gene expression profiles in responsive versus nonresponsive tumors from mice before ICB.
- Validation of findings in human cancer patient cohorts treated with ICB antibodies.
- Experimental manipulation of the tumor microenvironment using interferon-γ (IFNγ), poly(I:C), and anti-interleukin-10 (IL-10) antibody in mice.
Main Results:
- Responsive tumors exhibit an inflammatory gene signature with up-regulated signal transducer and activator of transcription 1 (STAT1) and Toll-like receptor 3 (TLR3) signaling, and down-regulated interleukin-10 (IL-10) signaling.
- Increased infiltration of activated natural killer (NK) cells is essential for ICB response.
- Pretreatment with IFNγ, poly(I:C), and anti-IL-10 antibody enhanced ICB efficacy by promoting NK cell infiltration and increasing cure rates.
Conclusions:
- A specific pretreatment tumor microenvironment, characterized by inflammatory signatures and NK cell infiltration, predicts response to ICB.
- Therapeutic strategies targeting this microenvironment can sensitize tumors to ICB, leading to improved outcomes.
- Biomarker-driven patient management can identify individuals who would benefit from sensitizing therapies prior to ICB.
Related Concept Videos
The Tumor Microenvironment
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
Hypothalamic-Pituitary Axis
Neuromuscular Junction And Blockade
Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...

